We present Interactome InSIdER, a tool to link genomic variant information with structural protein-protein interactomes. Underlying this tool is the application of machine learning to predict protein interaction interfaces for 185,957 protein interactions with previously unresolved interfaces in human and seven model organisms, including the entire experimentally determined human binary interactome. Predicted interfaces exhibit functional properties similar to those of known interfaces, including enrichment for disease mutations and recurrent cancer mutations. through 2,164 de novo mutagenesis experiments, we show that mutations of predicted and known interface residues disrupt interactions at a similar rate and much more frequently than mutations outside of predicted interfaces. to spur functional genomic studies, Interactome InSIdER (http://interactomeinsider.yulab.org) enables users to identify whether variants or disease mutations are enriched in known and predicted interaction interfaces at various resolutions. Users may explore known population variants, disease mutations, and somatic cancer mutations, or they may upload their own set of mutations for this purpose.
been demonstrated that mutations tend to localize to interaction interfaces, and mutations on the same protein may cause clinically distinct diseases by disrupting interactions with different partners 6, 8 . However, the binding topologies of interacting proteins can only be determined at atomic resolution through X-ray crystallography, NMR, and (more recently) cryo-EM 9 experiments, which limits the number of interactions with resolved interaction interfaces.
To study protein function on a genomic scale, especially as it relates to human disease, a large-scale set of protein interaction interfaces is needed. Thus far, computational methods such as docking 10 and homology modeling 11 have been employed to predict the atomiclevel bound conformations of interactions whose experimental structures have not yet been determined. However, docked models are not yet available on a large scale; and while homology modeling has been used to produce models at scale 12 , it is only amenable to interactions with structural templates (<5% of known interactions). Together, cocrystal structures and homology models comprise the currently available precalculated sources of structural interactomes, covering only ~6% of all known interactions ( Fig. 1a,b) .
Here, we present Interactome INSIDER (integrated structural interactome and genomic data browser), a tool for functional exploration of human disease on a genomic scale (http://interactomeinsider.yulab.org). Interactome INSIDER is based on a structurally resolved, proteome-wide human interactome. We assembled this resource by building an interactome-wide set of protein interaction interfaces at the highest resolution possible for each interaction. We compiled structural interactomes by calculating interfaces in experimental cocrystal structures and homology models, when available. For the remaining ~94% of interactions, we applied a machine-learning framework to predict partner-specific interfaces by applying recent advances in coevolution-and docking-based feature construction 13, 14 . Interactome INSIDER combines predicted interaction interfaces for 185,957 previously unresolved interactions (including the full human Protein-protein interactions facilitate much of known cellular function. Recent efforts to experimentally determine protein interactomes in human 1 and model organisms [2] [3] [4] , in addition to literature curation of small-scale interaction assays 5 , have dramatically increased the scale of known interactome networks. Studies of these interactomes have allowed researchers to elucidate how modes of evolution affect the functional fates of paralogs 4 and to examine, on a genomic scale, network interconnectivities that determine cellular functions and disease states 6 .
While simply knowing which proteins interact with each other provides valuable information to spur functional studies, far more specific hypotheses can be tested if the spatial contacts of interacting proteins are known 7 . In the study of human disease, it has interactome and seven commonly studied model organisms) with disease mutations and functional annotations in an interactive toolbox designed to spur functional genomics research. It allows users to find enrichment of disease mutations at different scales: in protein interaction domains, in residues, and through atomic 3D clustering in protein interfaces.
RESULtS
To build Interactome INSIDER, we first constructed an interactome-wide set of protein interaction interfaces. While there are well-established methods for predicting whether two proteins interact 15, 16 , we focused on interactions that have been experimentally determined, but whose interfaces are unknown (Supplementary Note 1). For this task, there is a rich literature exploring the potential of many structural, evolutionary, and docking-based methods to predict protein interaction interfaces. However, so far none of these methods have been used to produce a whole-interactome data set of protein interaction interfaces (Supplementary Note 2).
We used ECLAIR (ensemble classifier learning algorithm to predict interface residues), a unified machine-learning framework, to predict the interfaces of protein interactions. ECLAIR leverages several complementary and proven classification features, including sequence-based biophysical features, structural features, and recently proposed features for predicting binding partner-specific interfaces, including coevolutionary 17, 18 and docking-based metrics 14 (Supplementary Note 3; Supplementary Figs. 1 and 2) . Unfortunately, many protein-protein interactions have missing features (especially structural features). In fact, this type of nonrandom missing-feature problem is present in many biological prediction studies and cannot be adequately resolved by commonly used imputation methods. To address this issue, ECLAIR is structured as an ensemble of eight independent classifiers, each of which covers a common case of feature availability. This unique structure of ECLAIR enables it to be applied to any interaction while using the most informative subset of available features for that interaction (Supplementary Notes 4 and 5; Supplementary Figs. 3 and 4) .
We comprehensively optimized hyperparameters for ECLAIR using a recently published Bayesian method, the tree-structured Parzen estimator approach (TPE) 19 , which allowed us to simultaneously tune up to eight hyperparameters for each subclassifier. We trained and tested each ECLAIR subclassifier using a set of known protein interaction interfaces, and we observed that interfaces can be predicted by the single, top-performing subclassifier available for each residue. Subclassifier performance increases with the number of features used. We observe an area under the ROC curve (AUROC) of 0.64 for our top-sequence-only subclassifier and AUROC of 0.80 for our top subclassifier using both sequence and structural features. In total, we used ECLAIR to predict the interfaces of 185,957 interactions with previously unknown interfaces, including for 115,576 human interactions ( Supplementary Fig. 5 ). Specifically, residues classified by ECLAIR with a high or very high interface potential have a precision of 0.69, and >90% of all 115,576 human interactions with predicted interfaces in Interactome INSIDER have one or more residues that fall into these categories. We supplemented known structural interfaces from cocrystalized proteins and homology models with our predictions to create structural interactomes at both the atomic and residue levels ( Fig. 2a) in seven model organisms and human (including all 122,647 human experimentally determined binary interactions reported in major databases; see Online Methods).
Comprehensive evaluation of predicted interfaces
We established that our predictions are of high quality through both machine learning and biological evaluation. We first evaluated the trade-offs between false-positive rate and truepositive rate and between precision and recall for each of the eight independent subclassifiers that compose ECLAIR. As expected, we find that as more informative features are added to subsequent classifiers, the areas under the ROC and precision-recall curves increase, and this justifies the use of classifiers trained on more features for residues where this information is available ( Supplementary Fig. 6 ).
We next compared ECLAIR with several other prediction methods through two independent validations. First, we used several readily available predictors [20] [21] [22] [23] [24] interactions in our testing set. We found that for the set of interactions for which all classifiers can predict, ECLAIR performs as well or slightly better than these methods by measures of precision, recall, true-positive rate and false-positive rate ( Fig. 2b and Supplementary Fig. 7 ). Finally, we applied ECLAIR to a standard external benchmark set of protein interaction interfaces 25 which has been used to evaluate the performance of ten other interface prediction methods 26 . We found that ECLAIR outperforms all benchmarked methods in accuracy and is comparable to the top performers in all other metrics ( Supplementary  Table 1 ). Furthermore, ECLAIR is applicable to any interaction, while methods in this benchmark rely on single-protein-structure inputs, which makes them much less applicable to genome-wide studies. In fact, 86.1% of interactions without structural features contain at least one predicted interface residue at an ECLAIR score corresponding to a precision ≥0.6.
We also performed >2,000 mutagenesis experiments to measure the rate at which population variants in our predicted interfaces disrupt interactions in comparison to variants within known cocrystal interfaces and noninterfaces (see Online Methods). Using our high-throughput yeast-two-hybrid assay 27 , we found that mutations in our predicted interfaces break their corresponding interactions at a significantly higher rate than those known to be away from the interface (P < 0.035) and at similar rates to mutations in known interfaces. Since it is known that mutations at protein interfaces are more likely to break interactions 6, 27 , our experimental results indicate that there is rich functional signal in our ECLAIR predictions ( Fig. 2c) .
Functional annotation of disease mutations in structural interactomes
Interactome INSIDER is a tool for identifying functionally enriched areas of protein interactomes and for browsing our multiscale structural interactome networks-198,503 protein interactions whose interfaces have been either experimentally determined, homology modeled, or predicted using ECLAIR. Interactome INSIDER also includes 56,159 disease mutations from HGMD 28 and ClinVar 29 and 1,300,352 somatic cancer mutations from COSMIC 30 with their per-disease, precalculated enrichment in protein interaction interfaces at the residue level, domain level, and through atomic clustering. The site includes information on >600,000 population variants from the Exome Sequencing Project 31 , 1000 Genomes Project 32 , and more 33 (see Online Methods). Users can search Interactome INSIDER by protein to retrieve all interaction partners and their interfaces, or they can search by disease to retrieve all interaction interfaces that are enriched for mutations of that disease. Additionally, users can upload their own set of mutations to find how they are distributed in the interactome and whether they are enriched in any protein interaction interfaces at the residue, domain, and atomic levels ( Fig. 3) .
We demonstrate the utility of Interactome INSIDER and the validity of its underlying database by investigating the functional and biological properties of our predicted interaction interfaces. We measured functional properties of our in silico predicted interfaces (those without prior experimental evidence) and compared these measurements to those of known interfaces from cocrystal structures. We found that disease mutations preferentially occur in our predicted interfaces at similar rates to those of known interface residues in PDB cocrystal structures ( Fig. 4a) , which indicates the viability of using predicted interfaces to study molecular disease mechanisms. Furthermore, each higher confidence bin of predicted interface residues is more likely to contain disease mutations than the previous, which shows that ECLAIR prediction scores are correlated with true protein function. We looked at the locations of somatic cancer mutations from COSMIC in our interface-resolved human interactome. We specifically focused on recurrent cancer mutations, as these are known to be more likely to be functional drivers 34, 35 . We found a marked enrichment of recurrent cancer mutations in our predicted interfaces compared to outside these interfaces (Fig. 4b) . The same trend is observed inside and outside of known interfaces from cocrystal structures, which suggests that the functional links between cancer and the potential disruption of protein interactions can be observed within the entire Interactome INSIDER human interface data set. We also looked at the distribution of population variants and show that their placement in and out of predicted interfaces matches that of known interfaces, with rarer mutations showing an enrichment in protein interfaces ( Fig. 4c) . Furthermore, population variants in our predicted interfaces are more likely to be damaging to protein function than variants outside of predicted interfaces, as predicted by PolyPhen-2 (ref. 36) ( Fig. 4d ) and EVmutation 37 (Fig. 4e) , matching the established trend for experimentally determined interfaces 38 . We validated many of these biological trends for interactions lacking structural features ( Supplementary Figs. 8-10 and Supplementary Note 6), and this suggests the utility of Interactome INSIDER even in feature-poor interactions and across different resolution scales. We used Interactome INSIDER to search for subnetworks in the human interactome that are enriched for mutations associated with a single disease by calculating the enrichment of disease mutations in interaction interfaces interactome wide. This identified the TGF-β/BMP signaling pathway, which is known to be involved in juvenile polyposis syndrome (JPS) 39 and contains multiple proteins harboring JPS mutations ( Fig. 5a) . We focused on a specific group of mutations in the SMAD4-SMAD8 interface, which can be found using 3D atomic clustering. Using our mutagenesis Y2H assay, we were able to test a JPS mutation (SMAD4 Y353S) 40 , which is at the interface of SMAD4-SMAD8, and show that it breaks this interaction, implicating SMAD8 in JPS ( Fig. 5a and Supplementary  Fig. 11 ). Although SMAD8 (also known as SMAD9) has not been reported to harbor JPS mutations in HGMD 28 , its involvement in the disease has been suggested 41 , and this shows the ability of Interactome INSIDER to implicate new proteins in disease. Y353S is not predicted by ECLAIR to be at the interface of SMAD4 and another of its binding partners, RASSF5. Indeed, through our Y2H experiment, Y353S does not break this interaction, demonstrating the functional insight Interactome INSIDER can provide about differential interfaces and how they might be relevant to understanding the molecular mechanisms of disease.
disease etiology revealed by partner-specific interfaces
Interactome INSIDER enables interrogation of different interfaces for the same protein, dependent upon its binding partner ( Fig. 5b) . For the study of protein function and disease, this is especially important, as a protein may maintain different functional pathways through different interfaces, and disruption of one interface may leave others intact 4, 8 . To test this on a large scale, we looked at pairs of disease mutations in the human interactome that appear at interaction interfaces, as predicted by ECLAIR. Similar to previous reports 8 , we observed that mutation pairs in the interface of two interacting proteins are much more likely to cause the same disease than mutation pairs in other interfaces of the same proteins that do not mediate the given interaction ( Fig. 5c) . We also find that mutation pairs on the same protein, but in separate interfaces with different binding partners, tend to cause different diseases (Fig. 5d) . This trend is observed in both known and predicted interfaces. These results indicate that Interactome INSIDER can be used to form functional hypotheses about the specificity of mutations to specific interactions and molecular pathways.
We next used Interactome INSIDER to find subnetworks in the human interactome enriched for mutations associated with a single disease. We uncovered a set of interacting proteins known to harbor mutations causal for hypertrophic cardiomyopathy (HCM) 42 and thereby recapitulated the core constituents of a known KEGG pathway related to the same disease ( Fig. 6) . These proteins were identified by enrichment of disease mutations in their shared interaction interfaces and, in the case of TNNI3-TNNC1, using cross-interface atomic clustering of disease mutation positions in 3D (features available via the Interactome INSDIER website). In addition to identifying known members of the HCM pathway, Interactome INSIDER also identified several additional proteins, including CSRP3, MYOM1, ANKRD, and TCAP, which are not part of the known KEGG pathway but carry HCM mutations enriched at their respective interaction interfaces with members of the pathway. We also identified a protein, TNNT1, which, although it contains no HCM mutations of its own, can be implicated in HCM through its interactions with the two proteins TPM1 and TNNC1, which are enriched for HCM mutations at their interfaces with TNNT1. Finally, we note that Interactome INSIDER reveals cases of partner-specific interfaces in this pathway. For instance, the known HCM pathway protein TTN's interface with ACTA1 is enriched for HCM mutations, and ACTA1 mutations are increasingly linked to HCM 43 . On the other hand, a separate interface of ACTA1 with its binding partner dystrophin is enriched with mutations causing a distinct disorder, actin myopathy 44 . This shows how ACTA1 can play roles in two different diseases through separate interaction interfaces with TTN and dystrophin and demonstrates Interactome INSIDER's unique ability to discover such cases of differential function mirroring differential interfaces.
dISCUSSIOn
We anticipate Interactome INSIDER will help bridge the divide between genomic-scale data sets and structural proteomic analyses. Now that large-scale sequencing data from many contexts are readily available, for instance from whole-genome and wholeexome population variant studies 31, 45 and cancer studies 46, 47 , researchers have become increasingly interested in ways to assess the potential functional consequences of variants on a genomic scale 48, 49 . Recently, we and others have developed methods to predict functional cancer driver mutations by finding hotspots of mutations in the structural proteome 35, 50 . With the comprehensive map of protein interfaces presented, we can now go a step further to predict specific etiologies of cancer and disease based on induced biophysical effects 51,52 that may break interactions. Because our interface map is partner specific, it can also be applied to predict pleiotropic effects, wherein several mutations in a single protein may affect different pathways depending upon which binding interfaces are mutated 8 . This could be the basis for designing new therapeutics and for rational drug design to selectively target specific protein functional sites 53 .
We have shown that hyperparameter optimization, which is surprisingly lacking in much of the current literature, can drastically improve the performance of classifiers for biological classification studies. The tiered ensemble form of the ECLAIR classifier represents a broadly applicable paradigm in practical machine learning that could be readily applied to solving other problems with large amounts of nonuniformly missing data, which very frequently occur in biology on account of study biases.
With future increases to the scale of biological databases from which we derive features, we expect that Interactome INSIDER will come to encompass even higher confidence predictions for many more interactions, thereby becoming increasingly applicable to functional studies. This may also address some limitations of structural databases today. For instance, the PDB is depleted of disordered proteins 54 , and it has been shown that disordered regions can form interfaces 55 . Since ECLAIR has not been trained on disordered interfaces, it is unlikely to predict new disordered interfaces. However, the ensemble classifier structure of ECLAIR uniquely positions it to incorporate all newly available evidence into interface predictions without sacrificing quality or scale, and this ensures a high-quality map of interaction interfaces now and in the future. Furthermore, the addition of new variants, especially cancer mutations and population variants from large-scale sequencing studies, will only increase the value of performing systems-level explorations with Interactome INSIDER.
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The authors declare no competing financial interests. Table 2) , as these are interactions where proteins are known to share a direct-binding interface that we can then predict 5 . In total, we curated 198,503 interactions in these eight species, including the full experimentally determined binary interactome in human (122,647 interactions) (Supplementary Note 1) . Those interactions with known interface residues based on available cocrystal structures in the Protein Data Bank (PDB) 70 were set aside for use in training and testing the classifier. Interactions without known interface residues comprise the set for which we make predictions.
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Testing and training sets for interface residue prediction. For those interactions with known cocrystal structures in the PDB, we calculate interface residues for their specific binding partners. To identify UniProt protein sequences in the PDB, we use SIFTS 71 , which provides a mapping of PDB-indexed residues to UniProt-indexed residues 33 . For each interaction and representative cocrystal structure, interface residues are calculated by assessing the change in solvent-accessible surface area of the proteins in complex and apart using NACCESS 72 . Any residue that is at the surface of a protein (≥15% exposed surface) and whose solvent-accessible surface area (SASA) decreases by ≥1.0 Å 2 in complex is considered to be at the interface. We aggregate interface residues across all available structures in the PDB for a given interaction, wherein a residue is considered to be at the interface of the interaction if it has been calculated to be at the interface in one or more cocrystal structures of that interaction (all other residues are considered to be away from the interface). In building our final training and testing sets, we only consider interactions for which aggregated cocrystal structures have combined to cover at least 50% of UniProt residues for both interacting proteins. The training and testing sets each include a random selection of 400 interactions with known cocrystal structures, of which 200 are heterodimers and 200 are homodimers ( Supplementary  Table 3 ). To ensure an unbiased performance evaluation, we disallowed any homologous interactions (i.e., interactions whose structures could be used as templates for homology modeling) between the training and testing set. We also disallowed repeated proteins between the two sets to avoid simply reporting a remembered shared interface between a protein and multiple binding partners.
Hyperparameter optimization with TPE. To train our ensemble of classifiers that comprise ECLAIR, we used the tree-structured Parzen estimator approach (TPE) 19 , a Bayesian method for optimizing hyperparameters for machine learning algorithms. TPE models the probability distribution p(x|y) of hyperparameters given evaluated loss from a defined objective function, L(x). We selected the following loss function to minimize based on classical hyperparameter inputs and residue window sizes:
where x is comprised of θ, a set of hyperparameters, and w, a set of residue window sizes. The evaluation metric, AUROC n , is the area under the roc curve for the n th left-out evaluation fold in a three-fold cross-validation scheme. We then used TPE to randomly sample an initial uniform distribution of each of our hyperparameters and window sizes and evaluate the loss function for each random set of inputs. TPE then replaces this initial distribution with a new distribution built on the results from regions of the sampled distribution that minimize L(x):
where y * is a quantile γ of the observed y values so that p(y < y * ) = γ. Importantly, y * is guaranteed to be greater than the minimum observed loss, so that some points are used to build l(x). TPE then chooses candidate hyperparameters to sample as those representing the greatest expected improvement, EI, according to the expression:
To maximize EI, the algorithm picks points x with high probability under l(x) and low probability under g(x). Each iteration of the algorithm returns x*, the next set of hyperparameters to sample, with the greatest EI based on previously sampled points.
Training the classifier. The ECLAIR classifier was trained in three stages, using a custom wrapper of the scikit-learn 73 random forest 74 classifier to allow for use of TPE to search both algorithm hyperparameters and residue window sizes simultaneously. In all cross-validations performed, we allowed TPE to search the following hyperparameters, beginning with uniform distributions of the indicated ranges: (i) minimum samples per leaf (0-1,000), (ii) maximum fraction of features per tree (0-1), and (iii) split criterion (entropy or gini diversity index). The number of estimators (decision trees) in each random forest was fixed at either 200 for training the feature selection classifiers or 500 for training the full ensemble. We also allowed TPE to search over residue window sizes (±0-5 residues for a total window of up to 11 residues, centered on the residue of interest). This was achieved by allowing extra features for neighboring residues to be included at the time of algorithm initialization.
In the first stage of training, cross-validation using TPE was performed on classifiers trained using only features from one of the five feature categories. The feature or set of features from each category with the minimum loss was selected to represent that category in building the ensemble classifier ( Supplementary  Table 4 ). In the second stage, the ensemble classifier was built of eight random forest classifiers, each trained on different subsets of feature categories, and hyperparameters and window sizes were again chosen using cross-validation and TPE (Supplementary Table 5 ). In the final stage, following performance measurement on the testing set, the eight subclassifiers were retrained using the full set of 3,447 interactions with at least 50% UniProt residue coverage in the PDB, using the same hyperparameters and window sizes found in the previous step.
Evaluating the ensemble. After training and optimizing using only the training set, we predicted interface residues in a completely orthogonal testing set. For each subclassifier of the ensemble, all residues in the testing set that could be predicted (given the full set of necessary features or a superset) were ranked according to their raw prediction scores to produce ROC and precision-recall plots.
Benchmarking against other methods. Interfaces for interactions in our testing set were computed using several popular interface prediction methods [20] [21] [22] [23] [24] . We compiled a set of representative protein structures from the PDB for each protein in our testing set, selecting the structure with the highest UniProt residue content based on SIFTS and excluding any PDB structures of interacting protein pairs from our testing set. We then evaluated the precision, recall, and false positive rate for proteins that were able to be classified by all methods. These represent point estimates of these metrics for the external methods with binary prediction scores.
We also compared ECLAIR with ten popular methods for interface prediction by predicting interfaces in a standard benchmark set of protein complexes 25 ( Supplementary Table 1 ). Here, we followed the experimental procedures laid out by Maheshwari et al. 26 and excluded complexes in which the receptor is <50 or >600 amino acids, where the interface is made up of <20 residues, or where multiple interfaces are present.
Predicting new interfaces. We retrained the ensemble using all available cocrystal structures, including those from both testing and training sets, a standard machine learning practice that makes maximum use of labeled data 75 . Using this fully trained ensemble of classifiers, we predicted interface residues for the remaining 185,957 interactions not resolved by either PDB structures or homology models. Subclassifiers were ordered based on the number and information content of features used in their training. Each residue was then predicted by only the top-ranking classifier of the ensemble trained on the full set or a subset of available features for that residue.
Interface enrichment and three-dimensional atomic clustering.
Interface domain enrichment, residue enrichment, and 3D atomic clustering can be calculated through the Interactome INSIDER web interface. For enrichments presented in this study, we accessed all disease mutations from the Human Gene Mutation Database (HGMD) 28 and ClinVar 29 , recurrent cancer mutations appearing ≥6 times in COSMIC 30 , and population variants from the Exome Sequencing Project 31 to compute the log odds ratio: where p 1 is the probability of a mutation or variant being at the interface, and p 2 is the probability of any residue being at the interface. We computed the log odds ratio for residues in each of the interface prediction potential categories. We also computed the log odds ratio for interactions with known interfaces from PDB cocrystal structures, defined as all known interface residues from NACCESS calculations and all residues in Pfam 76 domains with ≥5 interface residues. For the disease mutation enrichment analysis (Fig. 4a) , we used all disease mutations available from HGMD, and the following numbers of mutations occurred in each category: 10,196 very low; 10,547 low; 2,970 medium; 1,135 high; and 305 very high. We also computed enrichment of 18,638 mutations in known interfaces and 17,760 mutations in known noninterfaces (from cocrystal structure evidence).
To perform 3D atomic clustering of amino acid loci of interest, we used an established method 35 for clustering and empirical P value calculation and applied it to multiprotein clustering, wherein clusters can occur across an interaction interface. Here, we perform complete-linkage clustering 77 in the shared 3D space of both proteins, and iteratively, and randomly rearrange mutations in each protein to produce an empirical null distribution of cluster sizes.
Mutagenesis validation experiments.
We performed mutagenesis experiments in which we introduced random human population variants from the Exome Sequencing Project 31 into known and predicted interfaces. We randomly selected mutations of predicted interface residues in each of the top four ECLAIR categories (low-very high). As positive and negative controls, we also selected random mutations of known interface and noninterface residues in cocrystal structures in the PDB. The selected mutations were then introduced into the proteins according to our previously published Clone-seq pipeline 27 , and their impact (either disrupting or maintaining the interaction) was assessed using our yeast two-hybrid assay (Supplementary Note 7) . In this manner, we tested the impact of 2,164 mutations: 1,664 in our predicted interfaces and 500 in known interface and noninterface residues from cocrystal structures. In Figure 2c , we report the fraction of tested interface residue mutations that caused a disruption of the given interaction for each of the interface residue bins.
Web server. Interactome INSIDER is deployed as an interactive web server (http://interactomeinsider.yulab.org) containing known and predicted interfaces for 198,503 protein interactions in eight species as well as variants and functional annotations mapped relative to the residues in the human proteome. For each interaction, the most reliable, high-resolution model is presented-i.e., cocrystal structures are always displayed in lieu of homology models, and all remaining unresolved interactions are predicted by our ECLAIR classifier. Cocrystal structures are derived from the PDB, with extraneous chains removed for each interaction, and homology models are computed by MODELLER 11 and downloaded from Interactome3D 12 . For both types of structural model, we computed all residues at the interface over all available models and allow users to view any model from which a unique interface residue has been calculated. For predicted interfaces, a nonredundant set of single-protein models are shown when available, with locations of predicted interface residues indicated. In total, the resource contains 7,135 interactions with cocrystal structures, 5,411 with homology models, and 185,957 with predicted interfaces.
Interactome INSIDER also includes precalculated enrichment of mutations derived from several sources: 56,159 disease mutations from HGMD 28 and ClinVar 29 78 , and biophysical property change guides (i.e., polar to nonpolar, hydrophobic to hydrophilic) are also displayed for convenience. Mutation and variant-enrichment analyses can be triggered by the user for existing variants or for user-submitted sets within interacting protein domains, residues, and 3D clustering using the atomic coordinates of structures when available.
Downloads of known and predicted interface residues on a perinteraction basis are available as plain text and as .bed files that can be visualized alongside other genomic landmarks in the UCSC genome browser 79 . Per-protein visualization tracks, with interface residues of all interaction partners, are also available on the "Downloads" page, along with bulk downloads of interfaces for entire species. 
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